Syn3, a newly developed cyclic peptide and BDNF signaling enhancer, ameliorates retinal ganglion cell degeneration in diabetic retinopathy
Open Access
- 14 May 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Protein & Cell
- Vol. 15 (11) , 858-865
Abstract
Dear Editor,Keywords
Funding Information
- National Natural Science Foundation of China (81922025, 82371473, 82171080, 81970823, 82171461, 81771457, 82271107)
This publication has 13 references indexed in Scilit:
- Structure‐based design of peptidomimetic inhibitors of PSD‐95 with improved affinity for the PDZ3 domainFEBS Letters, 2023
- A PSD-95 peptidomimetic mitigates neurological deficits in a mouse model of Angelman syndromeProgress in Neurobiology, 2023
- Neuroprotective Factors of the Retina and Their Role in Promoting Survival of Retinal Ganglion Cells: A ReviewOphthalmic Research, 2021
- RELATIONSHIP BETWEEN STAGES OF DIABETIC RETINOPATHY AND LEVELS OF BRAIN-DERIVED NEUROTROPHIC FACTOR IN AQUEOUS HUMOR AND SERUMRetina, 2020
- Incidence and progression of diabetic retinopathy: a systematic reviewThe Lancet Diabetes & Endocrinology, 2019
- Antidepression action of BDNF requires and is mimicked by Gαi1/3 expression in the hippocampusProceedings of the National Academy of Sciences, 2018
- Impairment of TrkB-PSD-95 Signaling in Angelman SyndromePLOS Biology, 2013
- Retinal ganglion cells in diabetesThe Journal of Physiology, 2008
- Cyclic AMP controls BDNF-induced TrkB phosphorylation and dendritic spine formation in mature hippocampal neuronsNature Neuroscience, 2005
- Retinal ganglion cell survival is promoted by genetically modified astrocytes designed to secrete brain-derived neurotrophic factor (BDNF)Brain Research, 1994